Table 1 (abstract P486). Clinical characteristics of children with COVID-19 and AIDs
From: Proceedings of the 28th European Paediatric Rheumatology Congress (PReS 2022)
| Â | sJIA (n=21) | CAPS (n=7) | FMF (n=6) | BS (n=2) |
|---|---|---|---|---|
Sex (F/M) | 15/6 | 2/5 | 1/5 | 0/2 |
Age, years (Me[min;max]) | 13 [6;17] | 8[2;17] | 12[8;17] | 10 [3;17] |
COVID-19 with symptoms | 11(52%) | 5(71%) | 2(33%) | 1(50%) |
COVID-19 asymptomatic | 10(48%) | 2(29%) | 4(67%) | 1(50%) |
Treatment of RD | ||||
 DMARDs (methotrexate/csA) | 15/2 | 1 | 4 | 1 |
 Colchicine | 0 | 0 | 6 | 0 |
 Biologics | 16 | 5 | 2 | 1 |
 Etanercept | 2 | 0 | 1 | 0 |
 Adalimumab | 0 | 0 | 1 | 0 |
 Infliximab | 0 | 0 | 0 | 1 |
 Tocilizumab | 9 | 1 | 0 | 0 |
 Sarilumab | 3 | 0 | 0 | 0 |
 Canakinumab | 2 | 4 | 0 | 0 |
The activity stage of AID by the start of COVID-19 | ||||
 Remission | 14(67%) | 4(57%) | 1(16%) | 1(50%) |
 Low disease activity | 5(24%) | 2(29%) | 2(37%) | 1(50%) |
 High disease activity | 2(9%) | 1(14%) | 3(50%) | 0 |
Worsening/flare of AID after COVID-19 | 9(43%) | 0 | 1(17%) | 1(50%) |